Ourofino (BSP:OFSA3) Beneish M-Score: -2.05 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:OFSA3 Ourofino SA BSP:OFSA3
68 GF Score
Price R$26.80
GF Value R$26.86
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Ourofino Beneish M-Score?

Ourofino BSP:OFSA3 -2.19% 68 Beneish M-Score is -2.05 as of Jul. 14, 2026. GuruFocus rates BSP:OFSA3 with a GF Score™ of 68/100 and a GF Value™ of R$26.86 (Fairly Valued). The stock has 2 warning signs investors should review. Among 911 Drug Manufacturers companies, Ourofino ranks worse than 76.73% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.05 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Ourofino's Beneish M-Score or its related term are showing as below:

BSP:OFSA3' s Beneish M-Score Range Over the Past 10 Years
Min: -3.67   Med: -2.36   Max: -1.85
Current: -2.05

During the past 12 years, the highest Beneish M-Score of Ourofino was -1.85. The lowest was -3.67. And the median was -2.36.


Ourofino Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Ourofino's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ourofino Beneish M-Score Chart

Ourofino Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.02 -2.17 -3.53 -1.98 -1.89

Ourofino Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.10 -1.95 -1.98 -1.89 -2.05

BSP:OFSA3 vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ourofino's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ourofino Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ourofino's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ourofino's Beneish M-Score falls into.


BSP:OFSA3
68GF Score
Ourofino SA BSP:OFSA3
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ourofino Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ourofino for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0661+0.528 * 0.9619+0.404 * 0.9505+0.892 * 1.2412+0.115 * 0.9824
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.91+4.679 * 0.039313-0.327 * 0.9985
=-2.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was R$317 Mil.
Revenue was 250.469 + 419.727 + 356.505 + 259.194 = R$1,286 Mil.
Gross Profit was 134.942 + 219.518 + 188.347 + 133.296 = R$676 Mil.
Total Current Assets was R$1,098 Mil.
Total Assets was R$1,631 Mil.
Property, Plant and Equipment(Net PPE) was R$340 Mil.
Depreciation, Depletion and Amortization(DDA) was R$39 Mil.
Selling, General, & Admin. Expense(SGA) was R$111 Mil.
Total Current Liabilities was R$317 Mil.
Long-Term Debt & Capital Lease Obligation was R$460 Mil.
Net Income was 21.358 + 141.289 + 54.728 + 24.245 = R$242 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = R$0 Mil.
Cash Flow from Operations was 135.267 + 67.431 + -17.984 + -7.207 = R$178 Mil.
Total Receivables was R$239 Mil.
Revenue was 189.566 + 346.633 + 282.555 + 217.214 = R$1,036 Mil.
Gross Profit was 91.856 + 173.174 + 154.308 + 104.609 = R$524 Mil.
Total Current Assets was R$774 Mil.
Total Assets was R$1,267 Mil.
Property, Plant and Equipment(Net PPE) was R$335 Mil.
Depreciation, Depletion and Amortization(DDA) was R$38 Mil.
Selling, General, & Admin. Expense(SGA) was R$98 Mil.
Total Current Liabilities was R$302 Mil.
Long-Term Debt & Capital Lease Obligation was R$303 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(316.743 / 1285.895) / (239.351 / 1035.968)
=0.246321 / 0.231041
=1.0661

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(523.947 / 1035.968) / (676.103 / 1285.895)
=0.505756 / 0.525784
=0.9619

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1097.731 + 340.285) / 1630.836) / (1 - (774.331 + 335.433) / 1267.42)
=0.118234 / 0.124391
=0.9505

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1285.895 / 1035.968
=1.2412

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(37.585 / (37.585 + 335.433)) / (38.891 / (38.891 + 340.285))
=0.100759 / 0.102567
=0.9824

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(111.076 / 1285.895) / (98.335 / 1035.968)
=0.08638 / 0.094921
=0.91

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((460.365 + 316.914) / 1630.836) / ((302.902 + 302.062) / 1267.42)
=0.476614 / 0.477319
=0.9985

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(241.62 - 0 - 177.507) / 1630.836
=0.039313

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ourofino has a M-score of -2.05 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.05 mean?
Ourofino (BSP:OFSA3) has a Beneish M-Score of -2.05 as of Jul. 14, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ourofino and its competitors. According to the industry distribution chart, Ourofino ranks #699 out of 911 companies in the Drug Manufacturers industry, placing it in the top 76.7%.
Is Ourofino's Beneish M-Score too high?
Ourofino's current Beneish M-Score is -2.05. Based on the distribution chart, Ourofino ranks #699 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ourofino has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ourofino's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ourofino ranks #699 out of 911 companies for Beneish M-Score. This places Ourofino in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ourofino and its competitors. Ourofino's current Beneish M-Score is -2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ourofino stock overvalued right now?
Based on GuruFocus' analysis, Ourofino (BSP:OFSA3) is currently considered Fairly Valued. The stock's GF Value™ is R$26.86, compared to a current price of R$26.80 — trading 0.2% below its estimated fair value. The current Beneish M-Score is -2.05. Ourofino's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Ourofino (BSP:OFSA3), the current Beneish M-Score is -2.05 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ourofino (BSP:OFSA3) Overvalued in 2026?

Based on GuruFocus' analysis, Ourofino stock appears to be undervalued. The current stock price of R$26.80 is trading 0.2% below its estimated GF Value™ of R$26.86. GuruFocus considers Ourofino to be Fairly Valued.

Key valuation signals for BSP:OFSA3:

  • Beneish M-Score: -2.05
  • GF Value™: R$26.86 vs. price of R$26.80 (0.2% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the BSP:OFSA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ourofino Business Description

Address Anhanguera Highway SP 330, Block C, 2nd floor, Km 298, Industrial District, Cravinhos, SP, BRA, 14140-000
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
68GF Score

Get the complete analysis for BSP:OFSA3

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$26.80
Price
R$26.86
GF Value